CoChat

Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy

Open access
Piechnik, Matthew, Amendum, Paige C., Sawamoto, Kazuki, Stapleton, Molly, Khan, Shaukat, Fnu, Nidhi, Álvarez, Victor, Pachon, Angelica Maria Herreño, Danos, Olivier, Bruder, Joseph T., Karumuthil-Melethil, Subha, Tomatsu, Shunji · 2022 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.

Abstract

Adeno-associated virus (AAV) vector-based therapies can effectively correct some disease pathology in murine models with mucopolysaccharidoses. However, immunogenicity can limit therapeutic effect as immune responses target capsid proteins, transduced cells, and gene therapy products, ultimately resulting in loss of enzyme activity. Inherent differences in male versus female immune response can significantly impact AAV gene transfer. We aim to investigate sex differences in the immune response to AAV gene therapies in mice with mucopolysaccharidosis IVA (MPS IVA). MPS IVA mice, treated with different AAV vectors expressing human N-acetylgalactosamine 6-sulfate sulfatase (GALNS), demonstrated a more robust antibody response in female mice resulting in subsequent decreased GALNS enzyme activity and less therapeutic efficacy in tissue pathology relative to male mice. Under thyroxine-binding globulin promoter, neutralizing antibody titers in female mice were approximately 4.6-fold higher than in male mice, with GALNS enzyme activity levels approximately 6.8-fold lower. Overall, male mice treated with AAV-based gene therapy showed pathological improvement in the femur and tibial growth plates, ligaments, and articular cartilage as determined by contrasting differences in pathology scores compared to females. Cardiac histology revealed a failure to normalize vacuolation in females, in contrast, to complete correction in male mice. These findings promote the need for further determination of sex-based differences in response to AAV-mediated gene therapy related to developing treatments for MPS IVA.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232012693

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Cassette and study design. The experimental scheme of the first study was described by Sawamoto et al. [23]. AAV8: adeno-associated virus 8, ITR: inverted terminal repeat, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, D8: aspartic acid octapeptide, hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, RBG pA: rabbit β globin poly-A tail.
Figure 1 Cassette and study design. The experimental scheme of the first study was described by Sawamoto et al. [23]. AAV8: adeno-associated virus 8, ITR: inverted terminal repeat, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, D8: aspartic acid octapeptide, hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, RBG pA: rabbit β globin poly-A tail.CC BY · PubMed Central
Figure 2 Plasma hGALNS activity level of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight at 4 weeks old), (B) Group Two (mice treated with CAG promoter; 5 × 1013 GC/kg body weight at 4 weeks old), and Group Three (mice treated with TBG promoter; 2 × 1014 GC/kg body weight at 4 weeks old). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex cohort. hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.
Figure 2 Plasma hGALNS activity level of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight at 4 weeks old), (B) Group Two (mice treated with CAG promoter; 5 × 1013 GC/kg body weight at 4 weeks old), and Group Three (mice treated with TBG promoter; 2 × 1014 GC/kg body weight at 4 weeks old). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex cohort. hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.CC BY · PubMed Central
Figure 3 Plasma KS concentration of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. KS: keratan sulfate, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.
Figure 3 Plasma KS concentration of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. KS: keratan sulfate, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.CC BY · PubMed Central
Figure 4 Plasma anti-GALNS antibody concentration of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Concentrations are displayed as optical density absorption rates at the 405 nm wavelength. Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. GALNS: N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.
Figure 4 Plasma anti-GALNS antibody concentration of (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Concentrations are displayed as optical density absorption rates at the 405 nm wavelength. Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. GALNS: N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron, WT: wild-type.CC BY · PubMed Central
Figure 5 hGALNS activity in tissues for (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. Graphs are plotted on a logarithmic scale to better display distributions. hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron.
Figure 5 hGALNS activity in tissues for (A) Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (C) Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. Graphs are plotted on a logarithmic scale to better display distributions. hGALNS: human N-acetylgalactosamine-6-sulfate sulfatase, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron.CC BY · PubMed Central
Figure 6 (A) KS concentrations in liver and lung tissue for Group One (mice treated with the TBG promoter) and (B) KS concentrations in liver for Groups Two and Three (mice treated with the CAG and TBG promoter, respectively). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. KS: keratan sulfate, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron., F: female, M: male, WT: wild-type.
Figure 6 (A) KS concentrations in liver and lung tissue for Group One (mice treated with the TBG promoter) and (B) KS concentrations in liver for Groups Two and Three (mice treated with the CAG and TBG promoter, respectively). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. KS: keratan sulfate, TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron., F: female, M: male, WT: wild-type.CC BY · PubMed Central
Figure 7 Histopathology severity ratings for (A) femoral and tibial growth plates of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) femoral and tibial growth plates of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), (C) femoral and tibial growth plates of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight), (D) femoral and tibial articular cartilage of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (E) femoral and tibial articular cartilage of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), (F) femoral and tibial articular cartilage of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight), (G) femoral ligament and meniscus of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (H) femoral and tibial ligaments of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (I) femoral and tibial ligaments of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). All WT severity scores were zero. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron.
Figure 7 Histopathology severity ratings for (A) femoral and tibial growth plates of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (B) femoral and tibial growth plates of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), (C) femoral and tibial growth plates of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight), (D) femoral and tibial articular cartilage of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (E) femoral and tibial articular cartilage of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), (F) femoral and tibial articular cartilage of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight), (G) femoral ligament and meniscus of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight), (H) femoral and tibial ligaments of Group Two (mice treated with the CAG promoter; 5 × 1013 GC/kg body weight), and (I) femoral and tibial ligaments of Group Three (mice treated with the TBG promoter; 2 × 1014 GC/kg body weight). All WT severity scores were zero. * indicates a two-tailed t-test p-value of <0.05 compared to the WT cohort. ** indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort. TBG: thyroxine-binding globulin, CAG: a ubiquitous promoter including a cytomegalovirus enhancer element, a chicken β-actin promoter, and an intron.CC BY · PubMed Central
Figure 8 Toluidine blue staining of AAV8 CAG-hGALNS (Group Two) and TBG-hGALNS (Group Three) treated male and female (A) femoral growth plates, (B) tibial growth plates.
Figure 8 Toluidine blue staining of AAV8 CAG-hGALNS (Group Two) and TBG-hGALNS (Group Three) treated male and female (A) femoral growth plates, (B) tibial growth plates.CC BY · PubMed Central
Figure 9 Heart pathology scoring of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight) ranged from normal (0) to severe (1). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort.
Figure 9 Heart pathology scoring of Group One (mice treated with the TBG promoter; 5 × 1013 GC/kg body weight) ranged from normal (0) to severe (1). Error bars display standard deviation. * indicates a two-tailed t-test p-value of <0.05 compared to the opposite sex. # indicates a two-tailed t-test p-value of <0.05 compared to the untreated cohort.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 28

Metadata

Authors
Piechnik, M., Amendum, P. C., Sawamoto, K., Stapleton, M., Khan, S., Fnu, N., Álvarez, V., Pachon, A. M. H., Danos, O., Bruder, J. T., Karumuthil-Melethil, S., & Tomatsu, S.
Affiliations
  • Alfred I. duPont Hospital for Children (US)
  • Philadelphia College of Osteopathic Medicine (US)
  • Nemours/Alfred I. DuPont Hospital for Children, Wilmington, DE 19803, USA
  • Regenxbio (United States) (US)
  • REGENXBIO Inc., Rockville, MD 20850, USA
Corresponding author
Tomatsu, Shunji
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-10-21
Volume
23
Issue
20
Pages
12693
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4307263165
Cited by
28
References
64
Citations by year
2026: 4 · 2025: 15 · 2024: 7 · 2023: 2
FWCI
3.71
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • The Medicine Forum (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Austrian MPS society (1R01HD102545-01A1)
  • A Cure for Robert, Inc (1R01HD102545-01A1)
  • The Carol Ann Foundation (1R01HD102545-01A1)
  • Angelo R. Cali &amp; Mary V. Cali Family Foundation, Inc. (1R01HD102545-01A1)
  • The Vain and Harry Fish Foundation, Inc. (1R01HD102545-01A1)
  • The Bennett Foundation (1R01HD102545-01A1)
  • Jacob Randall Foundation (1R01HD102545-01A1)
  • Nemours Funds (1R01HD102545-01A1)
  • Institutional Development Award from the Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development of the National Institutes of Health (NICHD) (1R01HD102545-01A1)
  • REGENXBIO Inc. (1R01HD102545-01A1)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
mucopolysaccharidosis IVA, AAV8 gene therapy, sex differences, neutralizing antibodies, GALNS, N-acetylgalactosamine-6-sulfate sulfatase, lysosomal storage disease, articular cartilage, treatment efficacy
MeSH terms
Amino Acid Metabolism, Inborn Errors, Animals, Chondroitinsulfatases, Disease Models, Animal, Female, Humans, Male, Mucopolysaccharidoses, Mucopolysaccharidosis IV, Sex Characteristics, Genetic Therapy, Gene Expression, Capsid Proteins, Isovaleryl-CoA Dehydrogenase, Mice, Thyroxine-Binding Globulin, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.